These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16873282)

  • 1. CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes.
    Tsang CW; Lin X; Gudgeon NH; Taylor GS; Jia H; Hui EP; Chan AT; Lin CK; Rickinson AB
    J Virol; 2006 Aug; 80(16):8263-6. PubMed ID: 16873282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.
    Voo KS; Fu T; Heslop HE; Brenner MK; Rooney CM; Wang RF
    Cancer Res; 2002 Dec; 62(24):7195-9. PubMed ID: 12499257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1.
    Krüger S; Schroers R; Rooney CM; Gahn B; Chen SY
    J Immunother; 2003; 26(3):212-21. PubMed ID: 12806275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
    Lin X; Gudgeon NH; Hui EP; Jia H; Qun X; Taylor GS; Barnardo MC; Lin CK; Rickinson AB; Chan AT
    Cancer Immunol Immunother; 2008 Jul; 57(7):963-75. PubMed ID: 18094968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
    J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Cancer Sci; 2008 Aug; 99(8):1633-42. PubMed ID: 18754877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
    Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full-length EBNA1 mRNA-transduced dendritic cells stimulate cytotoxic T lymphocytes recognizing a novel HLA-Cw*0303- and -Cw*0304-restricted epitope on EBNA1-expressing cells.
    Ito Y; Demachi-Okamura A; Ohta R; Akatsuka Y; Nishida K; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    J Gen Virol; 2007 Mar; 88(Pt 3):770-780. PubMed ID: 17325349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.
    Marescotti D; Destro F; Baldisserotto A; Marastoni M; Coppotelli G; Masucci M; Gavioli R
    Immunology; 2010 Mar; 129(3):386-95. PubMed ID: 19922423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.
    Midgley RS; Bell AI; Yao QY; Croom-Carter D; Hislop AD; Whitney BM; Chan AT; Johnson PJ; Rickinson AB
    J Virol; 2003 Nov; 77(21):11507-16. PubMed ID: 14557636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.
    Long HM; Chagoury OL; Leese AM; Ryan GB; James E; Morton LT; Abbott RJ; Sabbah S; Kwok W; Rickinson AB
    J Exp Med; 2013 May; 210(5):933-49. PubMed ID: 23569328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
    Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
    Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.
    Leen A; Meij P; Redchenko I; Middeldorp J; Bloemena E; Rickinson A; Blake N
    J Virol; 2001 Sep; 75(18):8649-59. PubMed ID: 11507210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes.
    Rajnavölgyi E; Nagy N; Thuresson B; Dosztányi Z; Simon A; Simon I; Karr RW; Ernberg I; Klein E; Falk KI
    Int Immunol; 2000 Mar; 12(3):281-93. PubMed ID: 10700463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Construction and immunological responses of recombinant adenovirus containing Epstein-Barr nuclear antigen 1 in mice].
    Tong YY; Li HX; Zhang LX; Wang Z; Zhou L; Zeng Y; Du HJ
    Bing Du Xue Bao; 2014 Jul; 30(4):429-35. PubMed ID: 25272599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation.
    Voo KS; Peng G; Guo Z; Fu T; Li Y; Frappier L; Wang RF
    Cancer Res; 2005 Feb; 65(4):1577-86. PubMed ID: 15735048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.
    Nikiforow S; Bottomly K; Miller G; Münz C
    J Virol; 2003 Nov; 77(22):12088-104. PubMed ID: 14581546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
    Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies.
    Depil S; Moralès O; Castelli FA; Delhem N; François V; Georges B; Dufossé F; Morschhauser F; Hammer J; Maillère B; Auriault C; Pancré V
    J Immunother; 2007; 30(2):215-26. PubMed ID: 17471168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.